|
|
||||||||
J Thorac Cardiovasc Surg 2008;136:1450-1455
© 2008 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
a Institute of Cardiovascular Surgery, Xijing Hospital, the Fourth Military Medical University, Xi'an, China
b Department of Physiology, the Fourth Military Medical University, Xi'an, China
Received for publication January 14, 2008; revisions received February 22, 2008; accepted for publication March 20, 2008. * Address for reprints: Ding-Hua Yi, MD, PhD, Institute of Cardiovascular Surgery, Xijing Hospital, the Fourth Military Medical University, 17 Changle West Rd, Xi'an, China. (Email: yidinghua{at}yahoo.com.cn).
| Abstract |
|---|
|
|
|---|
Methods: One hundred thirty-four patients with congenital heart disease were randomly allocated to one of 3 groups according to the cardioplegia formula used: the high-potassium (HP) group (K+, 20 mmol/L), 46 patients; the high-potassium adenosine–lidocaine (HPAL) group (K+, 20 mmol/L; adenosine, 0.7 mmol/L; and lidocaine, 0.7 mmol/L), 44 patients; and the moderate-potassium adenosine–lidocaine (MPAL) group (K+, 10 mmol/L; adenosine, 0.7 mmol/L; and lidocaine, 0.7 mmol/L), 44 patients. Hemodynamic data during the operation and postoperative data were recorded. Serum cardiac troponin I concentrations were examined at the time points of before cardiopulmonary bypass and 1, 3, 6, 12, and 24 hours after aortic crossclamp removal.
Results: At the end of cardiopulmonary bypass and modified ultrafiltration, the systolic and pulse pressures of the MPAL group were significantly increased compared with the respective values of the HP group. At the time points of 1 to 12 hours after reperfusion, the levels of serum cardiac troponin I were significantly decreased in the MPAL group compared with those in the HP and HPAL groups.
Conclusions: The MPAL cardioplegia formula was associated with better myocardial protective effects.
| Introduction |
|---|
|
|
|---|
An alternative approach to arresting the heart is to maintain the transmembrane electrical potential in a polarized state,3
which locks the ion channels in a "closed" state. Therefore ionic imbalances and subsequent consequences are likely to be avoided.3
Adenosine triphosphate–sensitive potassium channel–opening agents (eg, nicorandil and aprikalim) have been used to achieve polarized or hyperpolarized arrest.2
However, potassium channel–opening agents have been reported to increase postischemic arrhythmias and myocardial oxygen demand on reperfusion and to produce profound systemic hypotension. For these reasons, hyperpolarized arrest with a potassium channel–opening agent as the arresting agent has not been adopted as a clinical cardioplegic strategy.
The combination of adenosine and lidocaine is an alternative method to achieve polarized arrest.4
In 2004, Corvera and colleagues4
reported the effects of normokalemic adenosine–lidocaine (AL) cardioplegia on an isolated rat heart perfusion model. The AL cardioplegia was based on Krebs–Henseleit solution, which contained 0.2 mmol/L adenosine and 5 mmol/L lidocaine and in which the potassium concentration was 5.9 mmol/L. The theory underlying the experiment was that this normokalemic AL cardioplegia solution could arrest the heart and meanwhile maintain the myocardial cell membrane potential at the normal level (about –83 mV), which might avoid ion-channel activation and extra energy consumption and in turn might improve a protective effect. In 2005, Corvera and associates5
reported their in vivo experimental study on a canine cardiopulmonary bypass (CPB) model, which demonstrated that the myocardial protective effects of warm or cold AL blood cardioplegia were equivalent to those of hypothermic potassium blood cardioplegia. The aim of this study was to investigate the cardioprotective effect of moderate-potassium AL cardioplegia in the clinical setting of pediatric cardiac surgery.
| Materials and Methods |
|---|
|
|
|---|
Composition of Cardioplegic Solutions
The basic cardioplegic solution was supplied by the clinical pharmacy of Xijing Hospital; 10% KCl solution, 2% lidocaine solution, and 0.3% adenosine solution were added before use by the perfusionist to achieve the various cardioplegic formulas. The compositions of the cardioplegic solutions are as follows:
Experimental Design
We performed a prospective, single-center, randomized controlled study. After patients provided informed consent, they were randomly allocated either to the HP cardioplegia group, the HPAL cardioplegia group, or the MPAL cardioplegia group. The randomization was realized by messages sealed in envelopes passed to the perfusionist just before the operation, with the surgeons and intensive care physicians being unaware of the allocation.
Study Population
Patients given diagnoses of congenital heart disease for which a clinical decision was made to treat with a cardiac operation were eligible for enrollment. Patients who were cocommitted with other systemic diseases or reoperation or had undergone right or left ventricular incision were not included. One hundred thirty-four patients who were admitted in the institute of cardiovascular surgery, Xijing Hospital, between March 1, 2007, and May 31, 2007, were included in the present study.
Table 1 summarizes the primary characteristics of the study population. There were no significant differences among the 3 groups with regard to age, sex, and body weight or defect types. The ratio of concomitant pulmonary hypertension among the 3 groups was also comparable, which indicated that the randomized allocation of the patients into 3 study groups was successful.
|
Postoperative Management
Routine continuous postoperative monitoring included surface electrocardiography, transcutaneous pulse oximetry, and systemic arterial pressure measurement. Inotropic, chronotropic, and afterload-reducing agents were used as clinically indicated. Volume infusions (usually PRBCs or 5% albumin) were administered to maintain adequate filling pressures with systolic perfusion pressures. Diuretics (usually furosemide, 1-2 mg · kg–1 per dose) were begun on the first postoperative morning or earlier if the patient was oliguric (<1 cm3 · kg–1 · h–1).
Measurement of Serum Cardiac Troponin I Concentrations
For each patient, six 2-mL blood samples were taken: at the induction of anesthesia and again 1, 3, 6, 12, and 24 hours after arrival in the intensive care unit (ICU). The blood was transferred into dry glass tubes and stored at 4°C to 8°C for clot formation before centrifugation. Serum separated after centrifugation was frozen at –70°C until assay. The serum cardiac troponin I (cTnI) concentration was measured in the Department of Clinical Laboratory of our hospital in duplicate with an Access AccuTnI assay (Beckman Coulter, Fullerton, Calif) system by individuals unaware of the group allocation.
Data Collection
Preoperative and postoperative data were collected prospectively by the study team from the day of surgical intervention until hospital discharge. The preoperative data included age, sex, and body weight. The operative data include CPB time; aortic crossclamp time; total volume of cardioplegia; lowest temperature during CPB; hematocrit value before the operation, during CPB, and at the end of the operation; total volume of fluid output (ultrafiltration plus urine volume) during the operation; and hemodynamic parameters, including blood pressure data before the start of CPB, after the discontinuation of CPB, and at the end of modified ultrafiltration (MUF). The postoperative data included the number of hours of mechanical ventilation in the ICU, the number of days in the ICU, total volume of blood transfusion, total volume of chest drainage, and length of hospitalization after the operation. Any complications after the operation were also recorded. Serial data, such as serum cTnI concentration at different time points, were measured as described above. The inotrope scores6,7,8
at different time points in the ICU were calculated as dopamine (x1) plus dobutamine (x1) plus amrinone (x1) plus milrinone (x15) plus epinephrine (x100) plus norepinephrine (x100) plus isoprenaline (x100).
Statistical Analyses
All continuous variables are expressed as means ± standard error of the mean, whereas discrete variables are presented as frequencies and percentages. Analyses of categorical variables were performed with the
2 test. Analysis of continuous variables was performed with a 2-way analysis of variance, and multiple comparisons were made with post hoc least-significant-difference comparisons.
| Results |
|---|
|
|
|---|
Comparison of Operative and Postoperative Parameters
As indicated in
Table 2, the preoperative and operative parameters among the 3 groups were comparable with regard to aortic crossclamp time, CPB time, cardioplegia volume, lowest body temperature during CPB, hematocrit value (before the operation, during CPB, and at the end of operation), and fluid output during the operation.
|
Hemodynamic Changes During the Operation
Systolic and diastolic arterial pressures were recorded; pulse pressures were calculated according to the following equation: Pulse pressure=Systolic pressure–Diastolic pressure.
As indicated in
Table 3, these 3 parameters changed in the same fashion, decreasing at the end of CPB and then increasing at the end of MUF. They were similar before the start of the CPB among the 3 groups. At the end of CPB, the systolic and pulse pressures of the MPAL group were significantly increased compared with the respective values of the HP group (68 ± 2.1 vs 62 ± 1.5 mm Hg [P = .013] and 29 ± 1.5 vs 25 ± 0.9 mm Hg [P = .029], respectively). At the end of MUF, the systolic and pulse pressures of the MPAL group were significantly increased compared with the respective values of the HP group (81 ± 1.7 vs 73 ± 1.6 mm Hg [P = .001] and 36 ± 0.9 vs 29 ± 1.1 mm Hg [P = .000], respectively). At the end of MUF, the systolic pressure of the HPAL group was increased compared with that of the HP group (78 ± 1.7 vs 73 ± 1.6 mm Hg [P = .030]), but the differences in pulse pressures between these 2 groups did not reach a statistically significant level (32 ± 1.1 vs 29 ± 1.1 mm Hg [P = .092]).
|
|
|
| Discussion |
|---|
|
|
|---|
Correlation Between Cell Membrane Potential and Potassium Concentration in Cardioplegia
The cell membrane potential (VM in millivolts) can be calculated from the Nernstian distribution of K+ ions between the extracellular and intracellular phases as follows4
:
|
|
Mechanisms for MPAL Cardioplegia's Superiority Over HP Cardioplegia
The mechanisms for MPAL cardioplegia's superiority over HP cardioplegia were not investigated in the present study but have previously been extensively discussed by Dobson.6
We summarize the main points as follows.
First, combined use of adenosine and lidocaine is related to better preservation of adenosine triphosphate, phosphocreatine, and glycogen stores and maintenance of a high cytosolic phosphorylation ratio during arrest, ischemia, and reperfusion.
Second, adenosine activates the A1 receptor subtype to exhibit its negative chronotropy, negative dromotropy, and negative inotropy, which contribute to arresting the heart. Furthermore, A1 receptor activation has been linked to the opening of the sarcolemmal adenosine triphosphate–sensitive K+ channel, stabilization of mitochondria mitochondrial permeability transition pore, and inhibition of the stimulatory effects of catecholamines.
Third, Lidocaine can block cardiomyocyte fast Na+ channels and effectively clamp the cell membrane near its resting membrane potential. Because fewer ion channels or pumps are activated at polarized potentials, the drug might reduce energy-sparing effects.
Fourth, because of fast Na+-channel blockade, the lidocaine and adenosine combination might further reduce Na+ and Ca++ loading.
Fifth, superior arrest and protection might also relate to the coronary vasodilatory properties of adenosine, lidocaine, and low potassium concentration, which result in reduced coronary vascular resistance and greater delivery of cardioplegia. This had been confirmed by the study of Dobson.4
Sixth, concentrations of potassium of greater than 15 mmol/L have been linked to left ventricular dysfunction and endothelial damage, and these deleterious effects are concentration dependent. Our results support these experimental studies and show that MPAL cardioplegia is linked with better hemodynamic features, including higher systolic pressures and pulse pressures at the end of CPB and MUF compared with the HP and HPAL groups.
Limitations of the Study
One of the limitations of this study was that the patients included in the study were all committed with simple congenital heart defects without cyanosis, and therefore the significance of the results might be very limited. Another limitation of this study was that we used systolic and pulse pressures to evaluate the hemodynamic performances of different groups. Because the pressure measurements were load dependent, this somewhat impaired their significance as perfect parameters of heart functions during the operation. Considering this was a controlled, blind, and randomized study, the pressure measurements still had some values to reflect the hemodynamic differences. The most important limitation of this study was that the cardioplegic formula we used was not a normokalemic one, which is somewhat different from Dobson's studies. A normokalemic cardioplegic solution might be better than the MPAL solution we used here, and the newest evidence from Dobson's laboratory9
showed that normokalemic AL cardioplegia could be delivered intermittently or continuously with similar functional recoveries after a 40- or 60-minute arrest at 33°C in an isolated, perfused rat heart model. For safety reasons, we did not try the normal-potassium AL formula in a clinical setting. Corvera and associates5
demonstrated that intermittent polarized arrest with warm or cold AL blood cardioplegia provided the same degree of myocardial protection as intermittent hypothermic K+–blood cardioplegia in a canine CPB model, but the AL solution did not show any superiority to traditional hyperkalemic cardioplegia. Whether normal-potassium AL cardioplegia is as safe and effective as MPAL cardioplegia in a clinical setting requires more experimental investigation.
| Conclusion |
|---|
|
|
|---|
| Acknowledgments |
|---|
| Footnotes |
|---|
* Drs Jin and Zhang contributed equally to this article. ![]()
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. M. Rudd and G. P. Dobson Eight hours of cold static storage with adenosine and lidocaine (Adenocaine) heart preservation solutions: Toward therapeutic suspended animation J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): 1552 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wu, P. Dong, C. Chen, J. Yang, and X. Hou The Myocardial Protection of Polarizing Cardioplegia Combined With Delta-Opioid Receptor Agonist in Swine Ann. Thorac. Surg., June 1, 2011; 91(6): 1914 - 1920. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jin, W. Duan, M. Chen, S. Yu, H. Zhang, G. Feng, L. Xiong, and D. Yi The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial Eur J Cardiothorac Surg, May 1, 2011; 39(5): e90 - e96. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.- H. Lee, H.- M. Lee, C.- H. Chung, J.- H. Chin, D.- K. Choi, H.- J. Chung, J.- Y. Sim, and I.- C. Choi Impact of intravenous lidocaine on myocardial injury after off-pump coronary artery surgery Br. J. Anaesth., April 1, 2011; 106(4): 487 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Dobson Membrane polarity: A target for myocardial protection and reduced inflammation in adult and pediatric cardiothoracic surgery J. Thorac. Cardiovasc. Surg., December 1, 2010; 140(6): 1213 - 1217. [Full Text] [PDF] |
||||
![]() |
K. L. Sloots and G. P. Dobson Normokalemic adenosine-lidocaine cardioplegia: Importance of maintaining a polarized myocardium for optimal arrest and reanimation J. Thorac. Cardiovasc. Surg., June 1, 2010; 139(6): 1576 - 1586. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |